Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking

After UK Cancelled Order, EU Could Provide Lifeline

 
• By Andrew McConaghie

Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.

Valneva Livingston
Valneva has lost out on a deal with the UK government worth $1.24bn, and is now looking for other customers for its vaccine. • Source: Alamy

More from COVID-19

More from Scrip